Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: Correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging

Journal of Nuclear Medicine

Volumn 53, Issue 1, 2012, Pages 82-89

  Stillebroer, Alexander B ^a   Zegers, Catharina M L ^a   Boerman, Otto C ^a   Oosterwijk, Egbert ^a   Mulders, Peter F A ^a   O'Donoghue, Joseph A ^b   Visser, Eric P ^a   Oyen, Wim J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

cG250; Myelotoxicity; Predictive dosimetry; Radioimmunotherapy

Indexed keywords

INDIUM 111; LUTETIUM 177; YTTRIUM 90; DIAGNOSTIC AGENT; G250 MONOCLONAL ANTIBODY; INDIUM; LUTETIUM; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CLINICAL ARTICLE; DOSE RESPONSE; DOSIMETRY; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG UPTAKE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; ISOTOPE LABELING; KIDNEY CARCINOMA; LEUKOCYTE TOXICITY; MALE; PHASE 1 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE; RADIOIMMUNOTHERAPY; THROMBOCYTE TOXICITY; TREATMENT RESPONSE; TUMOR VOLUME; BLOOD; BONE MARROW; CLINICAL TRIAL; ELECTRON; KIDNEY TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; RADIATION EXPOSURE; RADIOMETRY; SCINTISCANNING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BETA PARTICLES; BONE MARROW; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDIUM RADIOISOTOPES; KIDNEY NEOPLASMS; LUTETIUM; MALE; MIDDLE AGED; RADIATION DOSAGE; RADIOIMMUNOTHERAPY; RADIOMETRY; RADIOTHERAPY DOSAGE;

EID: 84855402294     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.094896     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124. (Pubitemid 46089672)
3. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors: a review on pharmacology, metabolism and side effects. Curr Drug Metab. 2009;10:470-481.
4. DeNardo GL, Siantar CL, DeNardo SJ. Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy. Cancer Biother Radiopharm. 2002;17:107-118. (Pubitemid 34208175)
5. Shen S, DeNardo GL, Sgouros G, O'Donnell RT, DeNardo SJ. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med. 1999;40:2102-2106. (Pubitemid 30022028)
6. Visser E, Postema E, Boerman O, Visschers J, Oyen W, Corstens F. Software package for integrated data processing for internal dose assessment in nuclear medicine (SPRIND). Eur J Nucl Med Mol Imaging. 2007;34:413-421. (Pubitemid 46295350)
7. DeNardo DA, DeNardo GL, O'Donnell RT, et al. Imaging for improved prediction of myelotoxicity after radioimmunotherapy. Cancer. 1997;80(12, suppl): 2558-2566. (Pubitemid 28009512)
8. Siegel JA, Lee RE, Pawlyk DA, Horowitz JA, Sharkey RM, Goldenberg DM. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. Int J Rad Appl Instrum B. 1989;16:553-559. (Pubitemid 19237454)
9. Behr TM, Sharkey RM, Juweid ME, et al. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med. 1997;38:858-870. (Pubitemid 27251973)
10. 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med. 2005;46:850-858.
11. 131I] cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response. Clin Cancer Res. 2005;11:7178s-7186s.
12. Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol. 2001;39:181-194. (Pubitemid 32564871)
13. 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med. 2000;27: 766-777.
14. Divgi CR, Bander NH, Scott AM, et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res. 1998;4:2729-2739. (Pubitemid 28523499)
15. 131I-labeled anticarcinoembryonic antigen monoclonal antibodies. J Nucl Med. 1999;40:1609-1616.
16. 131I-tositumomab. J Nucl Med. 2010;51:1878-1884.
17. 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. J Nucl Med. 2000;41:952-958.
18. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol. 1997;15:1529-1537. (Pubitemid 27167389)
19. Lewis MR, Kao JY, Anderson AL, Shively JE, Raubitschek A. An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA. Bioconjug Chem. 2001;12:320-324. (Pubitemid 32235486)
20. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098.
21. Loevinger R, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculations. New York, NY: The Society of Nuclear Medicine; 1988.
22. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027. (Pubitemid 43733519)
23. International Commission on Radiological Protection (ICRP). Report of the Task Group on Reference Man. ICRP publication 23. Ottawa, Ontario, Canada: ICRP; 1975.
24. Sacco JJ, Botten J, Macbeth F, Bagust A, Clark P. The average body surface area of adult cancer patients in the UK: a multicentre retrospective study. PLoS ONE. 2010;5:e8933.
25. Koral KF, Huberty JP, Frame B, et al. Hepatic absorbed radiation dosimetry during I-131 metaiodobenzylguanidine (MIBG) therapy for refractory neuroblastoma. Eur J Nucl Med Mol Imaging. 2008;35:2105-2112.
26. Konijnenberg M, Melis M, Valkema R, Krenning E. de JM. Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. J Nucl Med. 2007;48:134-142. (Pubitemid 47555387)
27. Howell S, Shalet S. Gonadal damage from chemotherapy and radiotherapy. Endocrinol Metab Clin North Am. 1998;27:927-943. (Pubitemid 28564065)
28. Chatal JF, Saccavini JC, Gestin JF, et al. Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas. Cancer Res. 1989;49:3087-3094.
29. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;43:693-713. (Pubitemid 34507123)
30. 111In: an intrapatient comparison. Clin Cancer Res. 2003;9:3953S-3960S.